Cargando…
Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report
Hyperuricemia is associated with the progression of chronic kidney disease (CKD) and cardiovascular diseases. Topiroxostat, a selective xanthine oxidase inhibitor, effectively reduces serum uric acid (UA) levels and urinary albumin excretion (UAE) in CKD patients. A 50-year-old Japanese man was refe...
Autores principales: | Tanaka, Atsushi, Nakamura, Tsukasa, Sato, Eiichi, Node, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318337/ https://www.ncbi.nlm.nih.gov/pubmed/28074335 http://dx.doi.org/10.1007/s40268-016-0169-1 |
Ejemplares similares
-
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2014) -
Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study)
por: Kato, Sawako, et al.
Publicado: (2016) -
Effect of Lubiprostone on Urinary Protein Excretion: A Report of Two IgA Nephropathy Patients with Chronic Constipation
por: Takeshita, Mitsuhide, et al.
Publicado: (2019) -
Management of Hypertension in Chronic Kidney Disease
por: Pugh, Dan, et al.
Publicado: (2019) -
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
por: Hosoya, Tatsuo, et al.
Publicado: (2018)